AVTE
NASDAQAerovate Therapeutics Inc.
Website
News25/Ratings12
Latest news
25 items- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Lavelle Erin4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Klein Lawrence Otto4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Cain Christopher W.4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Dobmeier Eric4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERNew insider Fairmount Funds Management Llc claimed ownership of 3,220,368 shares (SEC Form 3)3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lavelle Erin3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERNew insider Klein Lawrence Otto claimed ownership of 86,215 shares (SEC Form 3)3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cain Christopher W.3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dobmeier Eric3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Balta Elizabeth3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kocinsky Hetal3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERNew insider King Andrew James claimed ownership of 344,863 shares (SEC Form 3)3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quick Jonathan3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Frohlich Tom3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- INSIDERLarge owner Ra Capital Management, L.P. acquired 1,062,326 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- SECSEC Form 10-Q filed by Aerovate Therapeutics Inc.10-Q - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- PRAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi
- SECSEC Form 425 filed by Aerovate Therapeutics Inc.425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)
- SECSEC Form 425 filed by Aerovate Therapeutics Inc.425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)